65,437 trials
Myocardial Infarction
Primary: Composite of Time to First Heart Failure Hospitalisation or All-cause Mortality — 6.58; 5.85 Pt with events/100 pt-years at risk — p=0.2061
Alzheimer Disease
Primary: Change in Connectivity Measure of the TGd Parcellations. — 0.5 abnormal connections
Satisfaction, Personal
Primary: User Satisfaction as Measured by the Client Satisfaction Questionnaire (CSQ-8) — 23.49; 23.97 score on a scale
Chronic Uncontrolled Gout · Gout · Uncontrolled Gout
Primary: Percentage of Participants Who Experienced an Infusion Reaction (IR), Including Anaphylaxis, Related to Pegloticase From Day 1 to Week 24 — 6.0; 0; 12.9 Percentage of…
Sleep Disturbance · Insomnia · Acute Coronary Syndrome
Primary: Percentage of Participants Who Complete 100% of the Outcome Assessments at Study Conclusion — 4; 7; 5 Participants
Healthy
Primary: Main Study: Number of Participants With Solicited Local and Systemic Adverse Events (AEs) for 7 Days Post-vaccination 1 — 21; 78; 6; 20 Participants
Eating Disorders · Type 1 Diabetes
Primary: Percentage of Time With Blood Sugar in Range as a Measure of Glycemic Control — 0.61; 0.63 percentage of time
Small Cell Lung Carcinoma Extensive Disease
Primary: Number of Patients With Adverse Events (AEs) Grade ≥ 3 — 77; 24 Participants
Recurrent Transformed B-Cell Non-Hodgkin Lymphoma · Refractory Transformed B-Cell Non-Hodgkin Lymphoma
Primary: Overall Response Rate (Combined Complete Response + Partial Response) — 6 Participants
Immunization; Infection
Primary: Antibody Prevalence Rate Against Anti-PRP With 1 μg/mL or Higher, Diphtheria Toxin, Pertussis, Tetanus Toxin, and Polio Virus, Defined as the Percentage of Participants…
Solid Tumors
Primary: Number of Participants With Any Treatment-Emergent Serious Adverse Events (TESAEs) — 7; 14 Participants
Binge Eating
Primary: Feasibility - Usage Rating Profile - Intervention — 5.44; 5.53 score on a scale
Myositis · Interstitial Lung Disease
Primary: % Predicted Forced Vital Capacity (FVC) Absolute Change — -1.70; -2.05 % predicted FVC — p=<0.05
Medication Adherence · Mobile Application
Primary: Usability of the SAM App — 1.14; 1.32; 1.35; 1.81 score on a scale
Systemic Scleroderma
Primary: EFS of Patients Undergoing Transplant — 15 participants